Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Voxtalisib||Phase I||Actionable||In a Phase I trial, SAR245409 (XL765) demonstrated safety and efficacy in patients with solid tumors (PMID: 18959794).||18959794|
|Unknown unknown||Advanced Solid Tumor||not applicable||Voxtalisib||Phase I||Actionable||In a Phase I trial, SAR245409 (XL765) reduced PI3K and mTORC1/mTORC2 pathway signaling and demonstrated safety and efficacy irrespective of molecular alterations in the PI3K pathway, in patients with advanced solid tumors (PMID: 24583798).||24583798|
|PubMed Id||Reference Title||Details|
|(24583798)||Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.||Full reference...|
|(18959794)||First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting.||Full reference...|